玻璃体内抗血管内皮生长因子治疗后的视网膜脉络膜病变

[Retinochoroidopathy after intravitreal anti-VEGF treatment].

作者信息

Maier M, Feucht N, Lanzl I, Kook P, Lohmann C P

机构信息

Augenklinik der Technischen Universität München, Deutschland.

出版信息

Ophthalmologe. 2009 Aug;106(8):729-34. doi: 10.1007/s00347-008-1839-3.

DOI:10.1007/s00347-008-1839-3

PMID:18953546

Abstract

A 74-year-old man presented with persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration. The diagnosis reached was retinochoroiditis as an occult manifestation of sarcoidosis, possibly resulting from an intravitreal injection of bevacizumab. The patient received a prescription for 100 mg Ultralan to be taken daily for 3 days and then tapered in 3 day steps. During the further course no deterioration of the condition was observed.

摘要

一名74岁男性在玻璃体内注射贝伐单抗治疗渗出性年龄相关性黄斑变性所致脉络膜新生血管2周后，出现右眼持续的视物变形。最终诊断为结节病隐匿表现的视网膜脉络膜炎，可能由玻璃体内注射贝伐单抗引起。患者接受了每日服用100mg优特灵（Ultralan）共3天，然后每3天减量的处方。在后续病程中未观察到病情恶化。